Dermatology · Rancho Cucamonga, CA
NPI
1427077684
Since 2006
Specialty
Dermatology
Code 207N00000X
Group practices
2
Medicare group memberships
Hospitals
0
Hospital affiliations
8200 Haven Avenue, Ste101
Rancho Cucamonga, CA, 91730
Phone (909) 649-8031
Groups this clinician bills Medicare through
Medicare paid, 2024
$32K
351 services
Medicare patients, 2024
144
Average age 67
Drug cost, 2024
$1.5M
2,255 prescriptions
Company payments, 2025
$2,319
From 15 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by David Opai-Tetteh was code 99213 (office e&m - established), 140 times for 95 patients. In total David Opai-Tetteh billed 351 services in 25 codes, and Medicare paid $32K.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2015-02-18.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| 99213 Office E&M - Established | Office | 140 | 95 | $77.81 | $11K |
| 88305 Surgical Pathology Examination | Office | 30 | 18 | $30.55 | $916 |
| 99214 Office E&M - Established | Office | 29 | 26 | $102.89 | $2,984 |
| 99203 Office E&M - New | Office | 26 | 26 | $90.25 | $2,346 |
| 11302 Removal or Shaving of Skin Growth | Office | 23 | 15 | $84.70 | $1,948 |
| 17110 Destruction Skin Lesion | Office | 14 | 12 | $103.18 | $1,445 |
Lab tests billed to Medicare, 2024
| Test code | Tests | Patients | Paid per test | Medicare paid |
|---|---|---|---|---|
| 88305 Surgical Pathology Examination | 30 | 18 | $30.55 | $916 |
Medicare prescription drug claims, 2024
In 2024, the drug David Opai-Tetteh prescribed most often to Medicare patients was Ammonium Lactate, with 155 prescriptions and refills. In total David Opai-Tetteh wrote 2,255 Medicare prescriptions that cost $1.5M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Ammonium Lactate Generic | 155 | 155 | 38 | $2,526 |
| Ketoconazole Generic | 153 | 159 | 63 | $3,108 |
| Fluocinolone Acetonide Generic | 137 | 138 | 54 | $6,857 |
| Montelukast Sodium Generic | 125 | 125 | 68 | $496 |
| Fluocinonide Generic | 120 | 120 | 49 | $5,305 |
| Tacrolimus Generic | 117 | 117 | 46 | $16K |
| Azelaic Acid Generic | 106 | 106 | 42 | $11K |
| Clobetasol Propionate Generic | 103 | 104 | 57 | $2,557 |
| Tretinoin Generic | 101 | 101 | 46 | $11K |
| Ciclopirox Generic | 98 | 98 | 41 | $3,180 |
| Calcipotriene Generic | 81 | 81 | 27 | $6,913 |
| Doxycycline Hyclate Generic | 80 | 80 | 71 | $422 |
| Betamethasone Dipropionate Generic | 72 | 72 | 35 | $2,296 |
| Terbinafine Hcl Generic | 71 | 71 | 35 | $410 |
| Dupixent Pen Dupilumab | 63 | 67 | 13 | $245K |
Brand drugs: 305 claims; generic drugs: 1,950 claims.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid David Opai-Tetteh $2,319 ($2,319 in general payments such as food, travel and fees) from 15 companies. The largest payer was Galderma Laboratories, L.P. with $363.
| Company | Payments | Amount |
|---|---|---|
| Galderma Laboratories, L.P. GALD.SW | 22 | $363 |
| LEO Pharma Inc. | 12 | $304 |
| UCB, Inc. UCB.BR | 7 | $290 |
| Janssen Biotech, Inc. JNJ | 9 | $269 |
| Novartis Pharmaceuticals Corporation NVS | 16 | $242 |
| Amgen Inc. AMGN | 21 | $225 |
| Incyte Corporation INCY | 5 | $116 |
| Pfizer Inc. PFE | 6 | $106 |
| Arcutis Biotherapeutics, Inc. ARQT | 5 | $102 |
| Botanix SB Inc | 4 | $84.96 |
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.